Halozyme Therapeutics (HALO) Change in Inventory (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Change in Inventory data on file, last reported at -$27.4 million in Q1 2026.

• Change in Inventory for Q1 2026 came in at -$27.4 million, down 4772.18% year-over-year; the trailing twelve-month figure through Mar 2026 was -$30.5 million (down 210.04% YoY), and the FY2025 annual result was -$2.6 million, down 103.79% from the prior year.
• Change in Inventory declined to -$27.4 million in Q1 2026 per HALO's latest filing, from -$18.8 million in the prior quarter.
• Over five years, Change in Inventory peaked at $40.2 million in Q1 2024 and troughed at -$27.4 million in Q1 2026.
• A 5-year average of $4.8 million and a median of $2.9 million in 2022 frame the typical range for Change in Inventory.
• The sharpest annual moves came in 2022 and 2026: Change in Inventory surged 17717.44% in 2022, then slumped 4772.18% in 2026.
• A 5-year view of Change in Inventory shows it stood at $2.9 million in 2022, then tumbled by 149.88% to -$1.5 million in 2023, then surged by 625.94% to $7.7 million in 2024, then plunged by 343.09% to -$18.8 million in 2025, then sank by 45.78% to -$27.4 million in 2026.
• Business Quant data shows HALO's Change in Inventory at -$27.4 million in Q1 2026, -$18.8 million in Q4 2025, and $1.1 million in Q3 2025.